Blood lead concentrations in sub-Saharan African children below 6 years: systematic review

Gerard Ngueta1, Ruth Ndjaboue

  • 1Population Health and Optimal Health Practices Research Unit, CHUQ Research Center, Laval University, Quebec, QC, Canada; Department of Social and Preventive Medicine, Faculty of Medicine, Laval University, Quebec, QC, Canada.

Insights

Blood lead levels in sub-Saharan African children are high, exceeding US standards. Urgent prevention programs and research are needed to address this public health concern.

Area of Science:

  • Environmental Health
  • Pediatric Health
  • Public Health

Background:

  • Elevated blood lead levels (BLLs) pose significant health risks to children.
  • Sub-Saharan Africa (SSA) faces a critical need to assess and mitigate lead exposure in young populations.

Purpose of the Study:

  • To determine the geometric mean of blood lead levels in children under six years old residing in sub-Saharan Africa.
  • To compare BLLs in SSA children with established international standards.

Main Methods:

  • A systematic literature search was conducted across MEDLINE, Web of Science, and Google Scholar.
  • Included studies focused on children under six years in SSA, with rigorous quality assessment of methods.
  • Data were extracted and synthesized using weighted means based on sample size.

Main Results:

  • Nine relevant studies from 11,148 identified papers reported a weighted mean BLL of 13.1 μg/dl.
  • Studies with higher methodological quality (venipuncture, quality control) showed a weighted mean BLL of 16.2 μg/dl.
  • Prevalence of BLLs ≥10 μg/dl ranged from 7.0% to 70.9% in six studies.

Conclusions:

  • Blood lead levels in SSA children remain significantly elevated compared to US children.
  • The current US CDC standard of 5 μg/dl highlights the urgent need for enhanced prevention programs and research in SSA.
  • Targeted interventions are crucial to reduce lead exposure and protect child health in the region.
Abstract

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...